At baseline, 13% of the women were taking an aromatase inhibitor. This rose to 44% by the end of the 24-month study.
基线水平上，13%的妇女正服用芳香化酶抑制剂。两年后，这一比例升高到了44%。
In addition, there was no increased risk of death from other causes in women who were prescribed the aromatase inhibitor.
另外服用芳香酶抑制剂的妇女的其他原因的死亡率没有增加。
In fact, the analysis showed that 132 patients must be treated with an aromatase inhibitor before one cardiovascular problem occurs.
实际上，这个分析显示132名患者在一个心血管疾病出现前，必须用芳香酶抑制剂治疗。
Women in the placebo group, not on an aromatase inhibitor, maintained BMD at the spine, but had a significant 1.2% loss at the total hip.
未服用芳香化酶抑制剂的妇女脊柱骨密度保持不变，全髋关节下降1.2%。
This makes the drugs much more tolerable. Millions of women worldwide take aromatase inhibitor therapy, and we may have another 'tool' to help them remain on it longer.
全世界有数百万的妇女接受芳香化酶抑制剂疗法，因此我们可以有另外的‘工具’帮助她们坚持服药(，延续生命)。
Steroidal aromatase inhibitor can inhibit the aromatase activity, interdict the reaction, and inhibit the estrogen formation, so that it can cure the breast cancer.
甾体芳香酶抑制剂能抑制芳香酶活性，阻断芳构化反应，抑制雌激素生成，从而达到治疗乳腺癌的目的。
Aromatase activities in gonads decreased significantly after implantation with aromatase inhibitor, but showed no significant difference between control and AI-implanted group.
此外，埋植AI后性腺芳香化酶活性显著降低，但脑部芳香化酶活性的变化不明显；
Objective: to compare the response and adverse reactions of aminoglutethimide with that of femara, an oral aromatase inhibitor, in postmenopausal women with advanced breast cancer.
目的观察弗隆和氨鲁米特治疗绝经后晚期乳腺癌的疗效和不良反应。
It is also approved for use in combination with an aromatase inhibitor for the treatment of postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer.
该药与芳香化酶抑制剂联合使用治疗HER2和激素受体共同阳性乳腺癌的绝经后女性。
It is also approved for use in combination with an aromatase inhibitor for the treatment of postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer.
该药与芳香化酶抑制剂联合使用治疗HER2和激素受体共同阳性乳腺癌的绝经后女性。
应用推荐